Exploring biomarkers for cognitive disorders in China
Cohort Study on Biomarkers of Cognitive Disorders in China
This study is trying to find early signs of dementia by following 3,000 people in China who have different stages of memory problems to see how their condition changes over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 40 Years to 90 Years |
| Sex | All |
| Sponsor | Xuanwu Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT06419101 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a large-scale dementia cohort in China by enrolling 3000 patients with pre-dementia stages and various dementia subtypes. It will collect comprehensive data, including demographics, clinical symptoms, neuropsychological assessments, neuroimaging, and biological samples. Participants will undergo annual follow-ups to monitor changes in their cognitive status, allowing researchers to compare clinical phenotypes and identify potential biomarkers for early diagnosis and progression of dementia. The study seeks to address the lack of longitudinal data on cognitive decline in the Chinese population.
Who should consider this trial
Good fit: Ideal candidates are Chinese individuals aged 40 to 90 who exhibit signs of cognitive decline.
Not a fit: Patients with severe cognitive impairment or other neurological diseases that could confound results may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods and early intervention strategies for dementia, enhancing patient outcomes.
How similar studies have performed: Other studies have successfully established dementia cohorts and identified biomarkers, suggesting that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female patients aged ≥40 and ≤90years; * Chief complaint or others describe a cognitive decline; * Ability to communicate in Chinese; * The patients and their families were informed and signed the informed consent. Exclusion Criteria: * MMSE\<10; * There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.); * There are other systemic diseases that can cause cognitive impairment (such as hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.); * Suffering from a disease that cannot cooperate with the completion of cognitive examination; * There are contraindications to nuclear magnetic resonance; * There is mental and neurodevelopmental delay; * Refuse to draw blood; * Refuse to sign the informed consent.
Where this trial is running
Beijing
- Capital Medical University Xuanwu Hospital — Beijing, China (Recruiting)
Study contacts
- Principal investigator: Cuibai Wei — Xuan Wu Hospital of Capital Medical University, Beijing, China, 100053
- Study coordinator: Cuibai Wei
- Email: weicb@xwhosp.org
- Phone: 83198319
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.